Published on Medical Design Technology (https://www.mdtmag.com)

Home > CytRx gets rare disease status for cancer therapy

CytRx gets rare disease status for cancer therapy

CytRx Corp. received special regulatory designation for an experimental drug meant to treat a type of cancer that affects soft tissue, the drug developer said Tuesday.

The Food and Drug Administration granted orphan drug designation, which awards certain tax and marketing incentives to drugmakers working on treatments for rare diseases. Generally the drug must be designed to treat diseases that affect less than 200,000 people.

The company's drug, INNO-206, is related to the chemotherapy therapy doxorubicin. CytRx plans to begin mid-stage trials of the drug in patients with soft tossue sarcoma in the second half of this year.

Shares of CytRx rose 3 cents, or 4.5 percent, to 71 cents in afternoon trading.

Content Item Type: 
News [1]
Meta Canonical URL: 
http://www.mdtmag.com/news/2011/07/cytrx-gets-rare-disease-status-cancer-therapy
Summary: 
CytRx Corp. received special regulatory designation for an experimental drug meant to treat a type of cancer that affects soft tissue, the drug developer said Tuesday.The Food and Drug Administration granted orphan drug designation, which awards certain tax and marketing incentives to...
Contributed Author: 
The Associated Press
Legacy NID: 
104 725

Deeper Insights

<% if ( rc.ss_related_image_url != null ){ %>
?cmpid=regwallcontent&utm_source=Deeper%20Insights">">
<% } %>

?cmpid=regwallcontent&utm_source=Deeper%20Insights" + ""><%- rc.label %>

<% if ( rc.ss_search_logo != null ){ %> <% } %>
Advertisement
googletag.cmd.push(function() { googletag.display("dfp-ad-clone_of_wallpaper"); });
(function() { var _fbq = window._fbq || (window._fbq = []); if (!_fbq.loaded) { var fbds = document.createElement('script'); fbds.async = true; fbds.src = '//connect.facebook.net/en_US/fbds.js'; var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(fbds, s); _fbq.loaded = true; } _fbq.push(['addPixelId', '745881082149515']); })(); window._fbq = window._fbq || []; window._fbq.push(['track', 'PixelInitialized', {}]);
(function(d,s,i,r) { if (d.getElementById(i)){return;} var n=d.createElement(s),e=d.getElementsByTagName(s)[0]; n.id=i;n.src='//js.hs-analytics.net/analytics/'+(Math.ceil(new Date()/r)*r)+'/1743435.js'; e.parentNode.insertBefore(n, e); })(document,"script","hs-analytics",300000);
var _qevents = _qevents || []; (function() { var elem = document.createElement('script'); elem.src = (document.location.protocol == "https:" ? "https://secure" : "http://edge") + ".quantserve.com/quant.js"; elem.async = true; elem.type = "text/javascript"; var scpt = document.getElementsByTagName('script')[0]; scpt.parentNode.insertBefore(elem, scpt); })(); _qevents.push({ qacct:"p-jsEPJWTckjCbE" });
Quantcast
googletag.cmd.push(function () { googletag.display("dfp-ad-roadblock_modal"); });
googletag.cmd.push(function() { googletag.display("dfp-ad-roadblock_modal"); });
Source URL: https://www.mdtmag.com/news/2011/07/cytrx-gets-rare-disease-status-cancer-therapy

Links
[1] https://www.mdtmag.com/content-item-types/news